Adiponectin and cancer: a systematic review.
Recent studies have demonstrated that obesity is a significant risk factor for the development of several malignancies, but the mechanisms underlying this relationship remain to be fully elucidated. Adiponectin, an adipocyte secreted endogenous insulin sensitizer, appears to play an important role not only in glucose and lipid metabolism but also in the development and progression of several obesity-related malignancies. In this review, we present recent findings on the association of adiponectin with several malignancies as well as recent data on underlying molecular mechanisms that provide novel insights into the association between obesity and cancer risk. We also identify important research questions that remain unanswered.
Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA, USA.
I
I
Kelesidis
T
T
Kelesidis
C S
CS
Mantzoros
D052242:Adiponectin / Q000502:physiology*; D004703:Endocrine System / Q000502:physiology*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D009369:Neoplasms / Q000503:physiopathology*; D009765:Obesity / Q000150:complications*; D011956:Receptors, Cell Surface; D012307:Risk Factors
D052242:Adiponectin; D011956:Receptors, Cell Surface; D005947:Glucose